Referenties bij artikel:

Transmurale samenwerking bevordert implementatie SGLT-2-remmers bij cardiovasculaire indicaties

FarmaMagazine | Editie 09 2021

1.           2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Heart Journal | Oxford Academic [Internet]. [geciteerd 5 oktober 2021]. Beschikbaar op: https://academic.oup.com/eurheartj/article/42/36/3599/6358045

2.           Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, e.a. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 7 september 2021;42(34):3227–337.

3.           Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, e.a. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 26 november 2015;373(22):2117–28.

4.           Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, e.a. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 8 oktober 2020;383(15):1413–24.

5.           McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, e.a. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 21 november 2019;381(21):1995–2008.

6.           Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, e.a. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 27 augustus 2021;0(0):null.

7.           Empagliflozin benefits heart failure patients with reduced and preserved ejection fraction EMPEROR-Pooled analysis presented in a Hot Line Session today at ESC Congress 2021 27 Aug 2021.

8.           Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, e.a. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 26 januari 2021;143(4):337–49.

Meer lezen? Schrijf u in voor de tweewekelijkse FarmaMagazine nieuwsbrief!

Vacatures

Sluit u aan bij meer dan 6.500 huisartsen en apothekers die tweewekelijks onze nieuwsbrief ontvangen over ontwikkelingen in de eerste lijn.